NewAmsterdam Pharma Company NV has published a document on the effects of obicetrapib, both alone and in combination with ezetimibe, on reverse cholesterol transport and VLDL production in mice. The research demonstrated that obicetrapib and ezetimibe reduce non-HDL-C levels by enhancing VLDL clearance and increasing LDL receptor expression. The study utilized APOE*3-Leiden.CETP mice to evaluate the mechanisms of obicetrapib and ezetimibe in a controlled setting. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.